Tagged with P

Pharma Legal Handbook 1. Are there proposals for reform or significant change to the healthcare system? Pre-project Law No. 12 which revokes law 462 of March 18, 2025, which modifies, adds to, revokes articles of law 51 of December 27, 2005, which reforms the organic law of the social security fund and enacts…

Pharma Legal Handbook Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in your country? Cannabinoids are substances subject to national control for therapeutic, medical, veterinary, scientific and research use.    2. What are the regulatory authorities with jurisdiction over Cannabinoid Drugs? The regulatory authorities are the Pharmaceutical and Drug Department from the Ministry of…

Pharma Legal Handbook Orphan Drugs in Panama are regulated by Law No. 419 of February 1, 2024, Executive Decree No. 13 of March 1, 2023 and Executive Decree 1217 of December 7, 2015; Rare Diseases are regulated by Law 28 of October 28, 2014.   1. What is the definition of Rare Diseases…

Pharma Legal Handbook BIOSIMILARS AND BIOLOGICS in Panama are regulated by Law No. 419 of February 1, 2024, Executive Decree No. 95 of May 14, 2019.   1. Are biosimilar medicines considered the same as generic medicines in your country? No. Generic medicines are defined as medicines distributed or sold that are marked…

France Launched in 2022 under the France 2030 biocluster programme, the Paris-Saclay Cancer Cluster (PSCC) is rapidly positioning itself as a new epicentre for oncology innovation in Europe. Under the leadership of CEO Benjamin Garel, it brings together world-class hospitals, leading universities, and major pharmaceutical partners with the mission of transforming…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast cancer programs, and Phrontline’s $60M funding to advance bispecific ADCs. Clinical breakthroughs feature BeOne’s zanidatamab + tislelizumab combo significantly improving…

Hong Kong GSK Hong Kong’s first year under Nicholas Teo marks a period of rapid evolution in the city’s healthcare system, from the strengthening of primary care to a deeper reliance on real world evidence and closer collaboration across government, academia and insurers. The affiliate is advancing a balanced portfolio in specialty…

Hong Kong With a strong heritage in Asia, DKSH has evolved into a leading force in connecting global healthcare innovation with local patient access. In this interview, Wai Ting Fong, VP Healthcare and Head Country Management at DKSH Hong Kong, shares how the organisation is shaping the region’s healthcare landscape, from pioneering…

USA John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning are at risk. Generics and biosimilars fill nine out of ten prescriptions yet account for a tiny slice of spending,…

USA Michael Petroutsas, President and Head of Astellas Pharma US, reflects on the company’s ongoing transformation and the market’s growing strategic importance within Astellas’ global organisation. He goes on to highlight Astellas’ focused therapeutic portfolio in oncology and specialty medicine, investments in advanced modalities like gene and cell therapy, and commitment…

Hong Kong After a challenging few years, the Hong Kong Stock Exchange (HKEX)’s IPO market bounced back strongly in 2025. By the end of Q3 2025, HK listings raised USD 23.9 billion across 66 IPOs (up 192 percent vs the previous year). Pre-revenue biotech listings, predominantly from mainland China, are also up…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s Hong Kong IPO for its next-gen TCE platform, Mindray Medical’s IPO for global expansion, and transformative deals like Third Arc…